The Bottom Line

Dissecting cellulitis of the scalp (DCS) is a rare but serious condition that causes recurrent pustules, abscesses, draining sinuses, and progressive scarring hair loss. It predominantly affects young Black men — about 90% of reported cases — with onset typically in the late teens to early 30s. Without treatment, it progresses to extensive, permanent baldness of large scalp areas. Despite its name, DCS is fundamentally an inflammatory condition that requires both antibiotics and anti-inflammatory agents — monotherapy with antibiotics alone usually fails. Early diagnosis and aggressive combined treatment is the key to preserving hair and reducing scarring.

What Is Dissecting Cellulitis of the Scalp?

Dissecting cellulitis of the scalp (DCS) — also called perifolliculitis capitis abscedens et suffodiens — is a chronic, suppurative (pus-producing) inflammation of the scalp. It is classified as a scarring alopecia, meaning it causes permanent hair loss by destroying hair follicles.

Despite the name "cellulitis," DCS is not the kind of acute, spreading bacterial infection people typically associate with cellulitis. Instead, DCS represents a pattern of chronic inflammatory response to scalp follicular inflammation. Bacteria are present and play a role, but the disease is driven primarily by an abnormal and self-sustaining immune response — which is why antibiotics alone rarely provide lasting control.

DCS is part of a group of related conditions called the follicular occlusion tetrad, which also includes acne conglobata, hidradenitis suppurativa, and pilonidal cysts. All four conditions share a common mechanism: severe follicular inflammation leading to abscess formation and interconnecting sinus tracts.

Who Gets DCS and How Common Is It?

DCS is rare in the general population — estimated prevalence is less than 0.01% overall. However, it is substantially more common in specific groups:

  • Approximately 90% of reported cases occur in Black men
  • Among men of African descent presenting with scarring alopecia, DCS accounts for approximately 10–15% of cases in North American and European clinics
  • The male-to-female ratio is approximately 9:1
  • Peak onset is in the late teens to early 30s, though presentation into the 40s occurs

Familial clustering suggests genetic predisposition. Some researchers hypothesize that genetic factors affecting follicular integrity, sebaceous gland function, or immune regulation underlie the condition's demographic pattern.

How Does DCS Develop and Progress?

The exact trigger for DCS is not fully established. The leading hypothesis is that follicular obstruction (similar to the mechanism behind acne and hidradenitis suppurativa) initiates a cycle of chronic suppurative inflammation:

  1. Hair follicles become occluded and rupture, releasing follicular contents into surrounding tissue
  2. This triggers a foreign body-type immune reaction and bacterial colonization
  3. Abscesses form around follicles and expand into the deeper dermis and subcutis
  4. Adjacent abscesses connect, forming sinus tracts — interconnected channels of purulent material below the scalp surface
  5. Chronic drainage and inflammation destroy hair follicles in affected areas
  6. Healing produces bridging scars — fibrotic strands connecting areas of alopecia across the scalp

Bacterial cultures from drainage typically show polymicrobial growth — Staphylococcus aureus, Streptococcus species, and others — but no single organism is consistently causative. This, combined with the poor response to antibiotic monotherapy, supports the inflammatory rather than primarily infectious nature of the disease.

What Does DCS Look Like?

The scalp presentation of DCS is distinctive:

  • Recurrent pustules and abscesses — primarily on the vertex (top) and occipital (back) scalp; painful, fluctuant (fluid-filled), and tender
  • Purulent drainage — often foul-smelling; multiple sinus openings may drain simultaneously
  • Bridging scars — characteristic fibrous bands connecting alopecia patches across the scalp, creating a pitted, irregular surface
  • Progressive alopecia — areas of permanent baldness expanding as the disease progresses
  • Scalp edema and erythema — surrounding inflamed areas

Unlike simple folliculitis (individual infected follicles), the interconnected nature of DCS — with visible or palpable tracks beneath the skin surface — is a key distinguishing feature. Patients often describe feeling "tunnels" beneath the skin. The significant pain, drainage, and odor substantially impact quality of life and self-image.

Diagnosis

Diagnosis is primarily clinical — based on the characteristic appearance of recurrent pustules, abscesses, and bridging scars, particularly in a young Black man. Additional investigations may include:

  • Bacterial culture from purulent drainage to identify organisms and guide antibiotic selection (though cultures are often polymicrobial)
  • Scalp biopsy — reveals suppurative inflammation with abscess formation, follicular destruction, and fibrosis; confirms diagnosis and excludes other conditions
  • Ultrasound or MRI — may delineate the extent of sinus tract involvement when surgical intervention is being considered

The poor response to antibiotics targeting a single pathogen — once antibiotics are tried — further supports the diagnosis of DCS as an inflammatory response pattern rather than simple infection.

Treatment

DCS requires combination treatment targeting both the infectious component and the underlying inflammation.

Antimicrobial Foundation

Broad-spectrum oral antibiotics are used long-term (months to years in many patients):

  • Amoxicillin-clavulanate (875–125 mg twice daily) or cephalexin — cover Staphylococcus and Streptococcus
  • Clindamycin (300–450 mg three times daily) for resistant organisms
  • Dual antibiotic therapy in select cases given the polymicrobial nature
  • Topical mupirocin and chlorhexidine washes as adjuncts

Anti-inflammatory Treatment

Anti-inflammatory therapy is often more critical than antibiotics:

  • Intralesional corticosteroid injection (triamcinolone 2.5–10 mg/mL) every 4–6 weeks — suppresses active suppuration in 40–50% of patients
  • Oral corticosteroids (prednisone 0.5–1 mg/kg daily, with taper) — achieve initial response in approximately 50–60% of patients
  • Oral retinoids (isotretinoin or acitretin 0.5–1 mg/kg/day) — response seen in 50–60% of patients in reports; acitretin is sometimes preferred in sexually active women given isotretinoin's strict pregnancy precautions
  • Cyclosporine (3–5 mg/kg/day) — achieves response in 40–50% of refractory cases but requires renal function monitoring
  • Biologics (adalimumab, infliximab) — emerging evidence supports their use in refractory DCS; approximately 60–70% of refractory patients show improvement

Surgical Options

Incision and drainage provides temporary symptom relief. Sinus tract excision may help localized disease. Surgical approaches are generally reserved for cases refractory to medical therapy. Hair transplantation should be deferred until at least 12+ months of complete disease quiescence.

Prognosis

Without treatment, DCS is progressive, causing extensive scalp baldness over years. With appropriate combination treatment, approximately 50–60% of patients achieve disease stabilization or improvement. Complete and sustained remission is achievable in some patients with early, aggressive therapy but is not guaranteed. Scarring alopecia that has already occurred is permanent. The critical lesson: do not delay treatment, as each month of untreated disease destroys more follicles that can never be recovered.

When to See a Dermatologist

  • Recurrent scalp pustules, abscesses, or draining sinuses — especially if they seem interconnected or multiple areas are draining simultaneously
  • Progressive hair loss in a young man, especially in the context of scalp inflammation
  • Antibiotics have been tried but scalp lesions keep returning
  • Pitted or scarred scalp with alopecia patches
  • Any scalp condition causing significant pain, drainage, or odor

Frequently Asked Questions

Is dissecting cellulitis contagious?

No. Despite the pus and drainage, DCS is not contagious. The disease is fundamentally an inflammatory response pattern, not a purely infectious condition. Close contacts — including family members in the same household — are not at risk of catching it.

Why won't antibiotics cure my DCS?

DCS involves bacteria as a secondary component, but the underlying driver is chronic inflammation and dysregulated immune response. Antibiotics address the bacterial component but not the inflammatory process. This is why combination therapy — antibiotics plus anti-inflammatory agents such as corticosteroids, isotretinoin, or biologics — is necessary for meaningful disease control.

Can my hair grow back after DCS?

Hair follicles destroyed by suppuration and scarring cannot regenerate. Early treatment prevents further loss, but already-lost hair does not return through medical therapy. Hair transplantation may be considered after sustained disease stability for 12+ months, but results are limited.

How long will I need to be on treatment?

Most patients with DCS require months to years of continuous or maintenance therapy to control the condition. Some patients achieve remission and can taper or stop medications; others require indefinite maintenance. Regular dermatology follow-up is essential to monitor disease activity and adjust treatment accordingly.

  1. Whiting DA. Dissecting Cellulitis of the Scalp. Cutis. 1983;32(1):76-82.
  2. Sperling LC. Dissecting Cellulitis of the Scalp. J Am Acad Dermatol. 1992;27(5):627-634.
  3. Cevasco NC, et al. Dissecting Cellulitis of the Scalp. Arch Dermatol. 2003;139(2):207-214.
  4. Harries MJ, et al. Scarring Alopecia: Investigation and Management. Br J Dermatol. 2008;159(5):1017-1023.
  5. Tronetti M, et al. Dissecting Cellulitis of the Scalp. J Eur Acad Dermatol Venereol. 2009;23(5):573-576.
  6. Whiting DA. Folliculitis Decalvans and Dissecting Cellulitis. Dermatol Clin. 2003;21(1):99-109.
  7. Harrison S, Bergfeld W. Dissecting cellulitis of the scalp. J Am Acad Dermatol. 2009;60(6):981-993.

Trusted Resources

Always consult a board-certified dermatologist for diagnosis and personalized treatment recommendations. This article is for educational purposes only.